GLP-1 drugs have transformed obesity treatment, but they come with a significant drawback: patients can lose muscle mass along with fat. This muscle loss is a concern because when patients stop taking the medication, they often regain the weight—primarily as fat rather than muscle.
Researchers are now exploring RNA therapy as a way to preserve muscle during GLP-1 weight loss. The approach is still in development, but the goal is to maintain lean tissue while patients shed fat, potentially improving long-term health outcomes and reducing the risk of weight regain.
If successful, this strategy could make GLP-1 treatment more sustainable by addressing one of its key limitations. However, the source does not provide details on the therapy's mechanism, trial stage, or efficacy, so further evidence is needed before any conclusions can be drawn.